Inherited Retinal Diseases: A Patient Guide
Schedule Today
How Inherited Retinal Diseases Are Classified
Because there are so many different inherited retinal diseases, specialists use several systems to organize and classify them. These classifications help guide diagnosis, prognosis, and treatment planning.
One common way to classify these conditions is by which type of photoreceptor is most affected. Rod-dominated diseases, such as retinitis pigmentosa, primarily affect rod photoreceptors, which are responsible for vision in low light. This causes night blindness and peripheral vision loss. Cone-dominated diseases, such as cone dystrophy and achromatopsia, primarily affect cone photoreceptors, which handle color vision and central detail. Some conditions affect both cell types, and the name (cone-rod or rod-cone dystrophy) reflects which is affected first.
The age at which symptoms first appear varies widely across different inherited retinal diseases. Leber congenital amaurosis causes severe visual impairment from birth or within the first months of life. Stargardt disease and Best disease typically appear in childhood or adolescence. Retinitis pigmentosa often begins with night blindness in the teenage years or young adulthood. Some forms of macular dystrophy may not cause noticeable symptoms until middle age. The timing of onset is an important clue for diagnosis and for understanding how a condition is likely to progress.
Some inherited retinal conditions are stationary, meaning vision remains relatively stable throughout life. Congenital stationary night blindness and achromatopsia are examples where a visual deficit is present from birth but does not meaningfully worsen. Progressive conditions, including retinitis pigmentosa, Stargardt disease, and choroideremia, involve ongoing degeneration of retinal cells with gradually worsening vision over years or decades. This distinction matters greatly for prognosis and for decisions about treatment and monitoring.
Many inherited retinal diseases affect only the eye. Others are part of broader genetic syndromes that also involve other organ systems. Usher syndrome, for example, combines retinitis pigmentosa with hearing loss. Bardet-Biedl syndrome involves retinal degeneration alongside kidney abnormalities, obesity, and other features. Identifying syndromic forms of retinal disease is important because early recognition of related health issues allows for appropriate monitoring and care of those conditions as well.
Common Types of Inherited Retinal Disease
While there are many different inherited retinal diseases, some are encountered more frequently than others. Becoming familiar with the most common types can help patients better understand their own diagnosis or a family member's condition.
Retinitis pigmentosa is the most common inherited retinal disease. It is characterized by the progressive loss of rod photoreceptors, followed over time by degeneration of cone photoreceptors. The typical course begins with night blindness and gradually narrowing peripheral vision, eventually affecting central vision in more advanced stages. Retinitis pigmentosa can be inherited in autosomal recessive, autosomal dominant, or X-linked patterns, and mutations in many different genes can cause it, making genetic testing especially valuable for accurate diagnosis.
Stargardt disease is the most common inherited macular dystrophy, meaning it primarily affects the central area of the retina responsible for sharp, detailed vision. It is most often caused by mutations in the ABCA4 gene and typically presents in childhood or adolescence with progressive central vision loss. The condition is associated with the buildup of a toxic byproduct called lipofuscin in the retinal pigment epithelium beneath the macula, damaging those support cells over time.
Leber congenital amaurosis is one of the most severe forms of inherited retinal disease, causing profound visual impairment from birth or the first year of life. Multiple different genes can cause this condition. The RPE65 gene is particularly significant because it is the target of the first gene therapy ever approved for an inherited retinal disease, offering a meaningful treatment option for patients with that specific genetic mutation.
Choroideremia is an X-linked condition that primarily affects males. It causes progressive degeneration of the choroid, the retinal pigment epithelium, and the photoreceptors. Symptoms typically begin with night blindness and peripheral vision loss in childhood or adolescence, while central vision is often preserved until later in life. Choroideremia is one of several inherited retinal diseases for which gene therapy is being actively studied in clinical trials.
Best disease, also called Best vitelliform macular dystrophy, is an autosomal dominant condition that primarily affects the macula. It is recognized by the accumulation of a yellow, egg-yolk-like deposit beneath the retinal pigment epithelium at the center of the retina. Best disease typically presents in childhood and progresses through several recognizable stages, with effects on central visual acuity that can vary considerably from person to person.
Treatment Options and Ongoing Research
The landscape of treatment for inherited retinal diseases has changed significantly, and research continues to expand what is possible. From approved gene therapies to emerging approaches still in clinical trials, there are meaningful reasons for hope, as well as important supportive tools available right now.
Voretigene neparvovec, sold under the name Luxturna, was approved by the FDA as the first gene therapy for an inherited retinal disease. It is designed for patients with biallelic RPE65 mutations, meaning mutations in both copies of the RPE65 gene. The therapy works by delivering a functioning copy of the RPE65 gene directly to retinal pigment epithelium cells through a carefully placed injection beneath the retina. Long-term data from clinical trials have shown sustained improvements in functional vision lasting up to a decade, and this approval established an important proof of principle for gene therapy in retinal disease.
Beyond the approved therapy, a growing number of gene therapy clinical trials are underway for other forms of inherited retinal disease. Active programs are targeting conditions including choroideremia, X-linked retinitis pigmentosa caused by RPGR mutations, Stargardt disease, Leber hereditary optic neuropathy, and several forms of Leber congenital amaurosis. These trials use a range of approaches, including delivering corrective gene copies using viral carriers, antisense oligonucleotides (molecules that can modify the behavior of a mutant gene), CRISPR-based gene editing, and optogenetic therapy (which introduces light-sensitive proteins into remaining retinal cells to restore some light response).
Researchers are also exploring treatment strategies that go beyond traditional gene replacement. RNA-based therapies can modify how a mutant gene is read by the cell, potentially reducing its harmful effects. CRISPR gene editing offers the possibility of correcting mutations directly within the patient's own DNA. Optogenetic therapy aims to restore light sensitivity to retinal cells that have lost their photoreceptors. Cell replacement therapy, using stem cell-derived retinal cells, is being investigated for patients with advanced disease who may have lost too many retinal cells for gene therapy alone to be effective. Each of these approaches is at a different stage of development and testing.
While gene-based treatments continue to advance, supportive care plays a vital role for patients at every stage of an inherited retinal disease. Low vision rehabilitation, which may include magnification devices, electronic reading aids, specialized lighting, and contrast-enhancing tools, helps patients make the most of their remaining vision. Orientation and mobility training supports safe and confident navigation for those with significant visual field loss. Educational and occupational accommodations help children and working adults function effectively despite visual limitations. These services can make a meaningful difference in quality of life and day-to-day independence.
When to Seek Specialist Care
Knowing when to see a retinal specialist is an important part of managing an inherited retinal disease, whether a diagnosis has already been made or symptoms are just beginning to appear. Timely evaluation opens the door to accurate diagnosis, genetic testing, and access to emerging treatments.
Anyone experiencing progressive night blindness, gradual loss of peripheral vision, difficulty with color vision, or unexplained central vision loss should be evaluated by a retinal specialist. These symptoms may have causes other than inherited retinal disease, but when they are present, especially in a younger person, a thorough retinal evaluation is warranted. If there is a known family history of retinal disease or unexplained vision loss running in the family, early evaluation is particularly important even before symptoms appear.
Patients who have a clinical diagnosis of an inherited retinal disease but have not yet undergone genetic testing should discuss this with their retinal specialist. A precise molecular diagnosis can change how a condition is managed and what treatments may be available. Genetic counseling helps patients understand what their results mean for themselves and for their children or siblings, allowing families to make informed decisions about testing and monitoring for other members who may be at risk.
Patients with inherited retinal diseases may want to ask their retinal specialist about clinical trial opportunities. The field is evolving rapidly, with new studies opening for different genetic subtypes of retinal disease on a regular basis. A specialist familiar with the current trial landscape can help determine whether a patient's specific genetic diagnosis and disease stage may make them a candidate for an ongoing or upcoming study, and can explain what participation would involve.
Frequently Asked Questions
These answers address common questions patients and families have after learning about inherited retinal diseases, with a focus on practical guidance and next steps.
Yes, and this is one of the most important things to understand about inherited retinal diseases. Even two patients diagnosed with the same condition, such as retinitis pigmentosa, may carry mutations in different genes or different variants of the same gene, leading to significant differences in how early the disease begins, how quickly it progresses, and which aspects of vision are affected first. This is why a molecular genetic diagnosis adds so much value on top of a clinical diagnosis, and why a specialist's guidance tailored to your specific situation is so important.
Absolutely. Autosomal recessive conditions require mutations in both copies of a gene, and both parents can be carriers without showing any symptoms themselves. In that case, the condition may appear to come out of nowhere with no prior family history. Spontaneous new mutations can also occur, meaning a person may carry a disease-causing mutation that was not inherited from either parent. Genetic testing and counseling can help clarify how a condition arose and what the implications are for other family members.
Eligibility for gene therapy or clinical trials is based on several factors, most importantly the specific gene and mutation causing your condition, as well as your disease stage and remaining retinal function. Luxturna, the currently approved gene therapy, is only for patients with biallelic RPE65 mutations. For other conditions, eligibility depends on what studies are actively enrolling and whether your diagnosis matches the trial's requirements. Your retinal specialist can review your genetic results and clinical findings together to help you understand your options, and specialists actively follow the evolving trial landscape to identify opportunities for their patients.
This decision depends on the inheritance pattern of your specific condition, your children's ages, and what would be done with the results. For dominant conditions, each child has a 50 percent chance of inheriting the mutation. For recessive conditions, the risk to children depends on whether the other parent also carries a relevant mutation. Genetic counseling is strongly recommended before pursuing testing in children, because a counselor can help weigh the benefits of early knowledge against the emotional and practical implications of testing minors for a condition that may not yet require treatment.
For most inherited retinal diseases, there is no proven lifestyle intervention that significantly slows progression, and patients should be cautious about unproven supplements or treatments. For specific conditions, a specialist may recommend protective measures such as UV-blocking eyewear. Avoiding smoking is generally good advice for overall retinal health. The most important step is staying engaged with a retinal specialist who can monitor your condition, keep you informed about new research, and connect you with supportive care services and clinical trials as they become available.
Take the Next Step for Your Vision
If you or a family member has been affected by an inherited retinal disease, our team is here to provide expert evaluation, personalized genetic testing guidance, and access to the latest treatment options. We are committed to staying at the forefront of retinal care so that our patients receive the most accurate diagnoses and the most current information about emerging therapies. We would be honored to support you on this journey and help you understand every aspect of your condition and your options.